heyboy
Banned
- Awards
- 0
what kind of prolactin controll supplements are good to use while on a 5 days on, 2 days off year round cycle of mk677?
and how often should you take em (dosages)?
and how often should you take em (dosages)?
alot of people are getting puffy nipples from mk677, and alot of people are recommending prolactin supplements while using mk677 on this forumHe doesn't need it for MK 677. It doesn't affect prolactin at all.
it was olympus labs ghar1ne, what brand do u recommend? brawn?At most temporary spike but nothing requiring concern unless you are worried about taking a research chemical for 6 months to a year.
I'd wager it was not pure MK.
https://www.ncbi.nlm.nih.gov/m/pubmed/9467534/
when people are getting puffy nipples from mk677 ill rather be safe than sorry, what kind of ingredients would controll prolactin?I'm telling you it doesn't raise prolactin as noted in the study I cited. Show me anywhere with MK it raises prolactin with blood tests.
I'm sorry. I cannot recommend any brands. Your 22 allegedly and have all the GH you need.
Times 2 on this! Inhibit P will be your best option when it comes to prolactin control. Definitely check it out and give it a try.SNS inhibit p has been recommended many times. Respected members have used this product with great results.
1. If you feel the need to control your prolactin. The suggestion made is good, as is Prolactrone from Black Lion Research.when people are getting puffy nipples from mk677 ill rather be safe than sorry, what kind of ingredients would controll prolactin? i know ashwagandha, vitamin E and zinc does it naturally, do i need anything stronger?
thanks but i cant buy that in my country, thats why im asking for ingredients and/or other optionsTimes 2 on this! Inhibit P will be your best option when it comes to prolactin control. Definitely check it out and give it a try.
somewhere in europeWhat country is that?
Yeah don't tell us your specific country otherwise someone will probably come find yousomewhere in europe
i dont have puffy nipples, and ive never used mk677, but i want to do research before i use it and have everything i need to battle side effectsThere are other reasons you could have puffy nipples other than high prolactin. Maybe you're just really bloated. MK will do that. Get bloodwork before you just assume that your prolactin levels are elevated.
lol I am pretty sure this guy is really like 13 because of his childish responses.Yeah don't tell us your specific country otherwise someone will probably come find you
Some type of GDA. It's known to raise resting BG and fast.what kind of prolactin controll supplements are good to use while on a 5 days on, 2 days off year round cycle of mk677?
and how often should you take em (dosages)?
Okay. Here's the thing. You are messing with hormones.MK does not raise prolactin lol. It can make you bloated though. I've ran it at high doses for months.
cant order from UK cus of customsIf you're in Europe you can get inhibit p
Just went to google.uk and found a number of U.K. Sites selling it.
Abstract
Obesity is associated with blunted GH secretion, unfavorable body composition, and increased cardiovascular mortality. The objective of this study was to investigate the effects of oral treatment with the GH secretagogue MK-677 on GH secretion and body composition in otherwise healthy obese males. The study was randomized, double blind, parallel, and placebo controlled. Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks. Serum insulin-like growth factor I (IGF-I) increased approximately 40% with MK-677 treatment (P < 0.001 vs. placebo). Serum IGF-binding protein-3 was also significantly increased (P < or = 0.001 vs. placebo). GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677. Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment. The increases in GH and PRL after the initial dose were significantly greater than the increase seen after multiple doses. Serum and urinary concentrations of cortisol were not increased at 2 and 8 weeks (P = NS, vs. placebo). Fat-free mass increased significantly in the MK-677 treatment group when determined with dual energy x-ray absorptiometry (P < 0.01) or using a four-compartment model (P < 0.05). Total and visceral fat were not significantly changed with active therapy. The basal metabolic rate was significantly increased at 2 weeks of MK-677 treatment (P = 0.01) but not at 8 weeks (P = 0.1). Fasting concentrations of glucose and insulin were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks. We conclude that 2-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3. The effects on cortisol secretion were transient. Changes in body composition and energy expenditure were of an anabolic nature, with a sustained increase in fat-free mass and a transient increase in basal metabolic rate. Further studies are needed to evaluate whether a higher dose of MK-677 or a more prolonged treatment period can promote a reduction in body fat.
Abstract
To determine the effect of the GH releasing peptide (GHRP)-mimetic, MK-677, on the GH/insulin-like growth factor-I (IGF-I) axis in selected GH-deficient adults, we studied nine severely GH-deficient men [peak serum GH concentration in response to insulin-induced hypoglycemia of 1.2 +/- 1.5 micrograms/L, mean +/- SD (range 0.02-4.79)], age 17-34 yr, height 168 +/- 1.5 cm, body mass index 22.6 +/- 3.3 kg/m2, who had been treated for GH deficiency with GH during childhood. In a double-blind rising-dose design, subjects received once daily oral doses of 10 or 50 mg MK-677 or placebo for 4 days over two treatment periods separated by at least 28 days. Four subjects received placebo and 10 mg/day MK-677 in a cross-over fashion in periods 1 and 2. Five subjects received 10 mg and then 50 mg/day MK-677 in a sequential, rising-dose fashion in periods 1 and 2, respectively. Blood was collected every 20 min for 24 h before treatment and at the end of each period for GH measurement using an ultrasensitive assay. The drug was generally well tolerated, with no significant changes from baseline in circulating concentrations of cortisol, PRL, and thyroid hormones. Serum IGF-i and 24-H mean GH concentrations increased in all subjects after treatment with both 10 and 50 mg/day MK-677 vs. baseline. After treatment with 10 mg MK-677, IGF-I concentrations increased 52 +/- 20% (65 +/- 6 to 99 +/- 9 micrograms/L, geometric mean +/- intrasubject SE, P < or = 0.05 vs. baseline), and 24 h mean GH concentrations increased 79 +/- 19% (0.14 +/- 0.01 to 0.26 +/- 0.02 microgram/L, P < or = 0.05 vs. baseline). Following treatment with 50 mg MK-677, IGF-I concentrations increased 79 +/- 9% (84 +/- 3 to 150 +/- 6 micrograms/L, P < or = 0.05 vs. baseline) and 24-h mean GH concentrations increased 82 +/- 29% (0.21 +/- 0.02 to 0.39 +/- 0.04 microgram/L, P < or = 0.05 vs. baseline), respectively. Serum IGF binding protein-3 concentrations increased with both 10 mg (1.2 +/- 0.1 to 1.7 +/- 0.1 micrograms/L, P < or = 0.05) and 50 mg MK-677 (1.7 +/- 0.1 to 2.2 +/- 0.2 micrograms/L, P < or = 0.05). The GH response to MK-677 was greater in subjects who were the least GH/IGF-I deficient at baseline; by linear regression analysis the increase in 24-h mean GH concentration was positively related to both baseline 24-h mean GH concentration (r = 0.81, P = 0.009) and baseline IGF-I (r = 0.79, P = 0.01) for 10 mg MK-677. IGF-I responses were not significantly related to any baseline measurement. Fasting and postprandial insulin and postprandial glucose increased significantly after MK-677 treatment, and the clinical significance of these changes will need to be assessed in longer term studies. Oral administration of such GHRP-mimetic compounds may have a role in the treatment of GH deficiency of childhood onset.
Abstract
The reversal of diet-induced negative nitrogen balance by GH suggests a possible therapeutic role for GH treatment in catabolic patients. A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism. Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods. During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily. There was a 14- to 21-day washout interval between periods. During the first week of caloric restriction (i.e. diet alone), daily nitrogen losses were similar for both treatment groups (mean +/- SE; MK-677 group -2.67 +/- 0.40 g/day vs. placebo group -2.83 +/- 0.26 g/day). During the second week (diet and study drug), mean daily nitrogen balance was 0.31 +/- 0.21 g/day in the MK-677 treatment group compared with -1.48 +/- 0.21 g/day in the placebo group (P < 0.01). MK-677 improved nitrogen balance integrated over the 7 days of treatment; area under the curve day 8-14 nitrogen balance response was +2.69 +/- 5.0 (SE) for MK-677 and -8.97 +/- 5.26 g.day for placebo (P < 0.001). MK-677 produced a peak GH response of 55.9 +/- 31.7 micrograms/L after single dose (day 1 of treatment) and 22.6 +/- 9.3 micrograms/L after a week of dosing compared with placebo treatment peak GH values of approximately 9 (treatment day 1) and approximately 7 micrograms/L (treatment day 7). Following the initial 7-day caloric restriction, insulin-like growth factor-I (IGF-I) declined from 232 +/- 25 to 186 +/- 19 ng/mL in the MK-677 group and from 236 +/- 19 to 174 +/- 23 ng/mL in the placebo group. Mean IGF-I concentration increased significantly during MK-677 to 264 +/- 31 ng/mL (mean for the last 5 days of treatment) compared with 188 +/- 19 ng/mL with placebo (P < 0.01). No significant difference in IGF binding protein-2 was found between the MK-677 and placebo treatments. However, the mean in IGF binding protein-3 for the last 5 days of MK-677 treatment was also significantly increased to 3273 +/- 330 ng/mL (mean +/- SE) compared with placebo 2604 +/- 253 ng/mL (P < 0.01). Neither the serum cortisol nor the PRL response was significantly greater after 7 days of MK-677 dosing compared with 7 days of placebo. MK-677 (25 mg) was generally well tolerated and without clinically significant adverse experiences. In conclusion, MK-677 reverses diet-induced nitrogen wasting, suggesting that if these short-term anabolic effects are maintained in patients who are catabolic because of certain acute or chronic disease states, it may be useful in treating catabolic conditions.
Abstract
BACKGROUND:
Growth hormone secretion and muscle mass decline from midpuberty throughout life, culminating in sarcopenia, frailty, decreased function, and loss of independence. The decline of growth hormone in the development of sarcopenia is one of many factors, and its etiologic role needs to be demonstrated.
OBJECTIVE:
To determine whether MK-677, an oral ghrelin mimetic, increases growth hormone secretion into the young-adult range without serious adverse effects, prevents the decline of fat-free mass, and decreases abdominal visceral fat in healthy older adults.
DESIGN:
2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
SETTING:
General clinical research center study performed at a university hospital.
PARTICIPANTS:
65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
INTERVENTION:
Oral administration of MK-677, 25 mg, or placebo once daily.
MEASUREMENTS:
Growth hormone and insulin-like growth factor I levels. Fat-free mass and abdominal visceral fat were the primary end points after 1 year of treatment. Other end points were body weight, fat mass, insulin sensitivity, lipid and cortisol levels, bone mineral density, limb lean and fat mass, isokinetic strength, function, and quality of life. All end points were assessed at baseline and every 6 months.
RESULTS:
Daily administration of MK-677 significantly increased growth hormone and insulin-like growth factor I levels to those of healthy young adults without serious adverse effects. Mean fat-free mass decreased in the placebo group but increased in the MK-677 group (change, -0.5 kg [95% CI, -1.1 to 0.2 kg] vs. 1.1 kg [CI, 0.7 to 1.5 kg], respectively; P < 0.001), as did body cell mass, as reflected by intracellular water (change, -1.0 kg [CI, -2.1 to 0.2 kg] vs. 0.8 kg [CI, -0.1 to 1.6 kg], respectively; P = 0.021). No significant differences were observed in abdominal visceral fat or total fat mass; however, the average increase in limb fat was greater in the MK-677 group than the placebo group (1.1 kg vs. 0.24 kg; P = 0.001). Body weight increased 0.8 kg (CI, -0.3 to 1.8 kg) in the placebo group and 2.7 kg (CI, 2.0 to 3.5 kg) in the MK-677 group (P = 0.003). Fasting blood glucose level increased an average of 0.3 mmol/L (5 mg/dL) in the MK-677 group (P = 0.015), and insulin sensitivity decreased. The most frequent side effects were an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain. Low-density lipoprotein cholesterol levels decreased in the MK-677 group relative to baseline values (change, -0.14 mmol/L [CI, -0.27 to -0.01 mmol/L]; -5.4 mg/dL [CI, -10.4 to -0.4 mg/dL]; P = 0.026); no differences between groups were observed in total or high-density lipoprotein cholesterol levels. Cortisol levels increased 47 nmol/L (CI, 28 to 71 nmol/L (1.7 microg/dL [CI, 1.0 to 2.6 microg/dL]) in MK-677 recipients (P = 0.020). Changes in bone mineral density consistent with increased bone remodeling occurred in MK-677 recipients. Increased fat-free mass did not result in changes in strength or function. Two-year exploratory analyses confirmed the 1-year results.
LIMITATION:
Study power (duration and participant number) was insufficient to evaluate functional end points in healthy elderly persons.
CONCLUSION:
Over 12 months, the ghrelin mimetic MK-677 enhanced pulsatile growth hormone secretion, significantly increased fat-free mass, and was generally well tolerated. Long-term functional and, ultimately, pharmacoeconomic, studies in elderly persons are indicated.
Derp, MK isn't hormonal, derp.Okay. Here's the thing. You are messing with hormones.
677 doesn't effect prl. Great! But it does effect other hormones, like igf, and hgh.
If someone's equilibrium is to have elevated prl levels ( and possibly estrogen) but say not as high hgh or igf, the addition of this hormonal disruption could be the key that unlocks breast tissue growth.
Gyno is commonly mistaken as being caused by estrogen or prolactin, when in fact it is caused by multiple hormonal disruptions, such as hgh, igf, prolactin, estrogen, etc.
Epistane makes me grow breast tissue at any dosage. I ran 90mg of trest inject for 5 month with zero supports, and no issues.
Hormonal disruption will vary. Who are you to say someone shouldn't cover their bases. Some people report gyno from using 677. Most don't.
You seriously need to learn about hormones and how they effect the body before telling someone they don't need something, cause the truth is, once you start messing with your hormones, you are basically juggling swords blindfolded hoping you don't stab yourself in the foot.
So far there have been multiple studies linked in this thread stating mk doesn't affect hormones like that.It is used to increase growth hormone and igf primarily. That is messing with your hormones.
Sigh. Newbs who fail to grasp hpta axis and changing that hormonal balance can cause issues.
Parallel to female breast development, estrogen, along with GH and IGF-1, is required for breast growth in males..
So your saying the compound people use to increase growth hormone doesn't increase growth hormone.....Are you reading the studies you are posting? I just looked at the last one and it has nothing to do with 677
I understand what your saying. Yes, I agree it can increase gyno. But I don't agree about the prolactin.You're failing to understand what I'm saying. Changes in hormones can cause unforeseen problems. The article you posted stated the same thing I already posted.
No one is saying 677 effects estrogen, test, dht, prolactin.
It increases hgh and igf.
So yes, if someone's baseline is higher estrogen and/or prolactin and they increase hgh and igf, this can lead to gyno.
The study gives you insight into how changes in hormones can effect someone.
It is not broscience. It's just how the body works.
I'm glad we finally have come full circle and you agree with what I said.
I use gharine, and enjoy it.
Thread starter | Similar threads | Forum | Replies | Date |
---|---|---|---|---|
ProSynthesis is finally here!!! Kind of... | MA Labs | 12 | ||
ProSynthesis is finally HERE!!! Kind of... | Supplements | 43 | ||
An oldie , I'm back, kind of | General Chat | 9 | ||
2 kinds of rebirth... | Supplements | 0 | ||
Newbie (kind of) | Supplements | 4 |